137 related articles for article (PubMed ID: 21497562)
1. American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer.
; Frank SJ; Arterbery VE; Hsu IC; Abdel-Wahab M; Ciezki JP; Hahn NM; Mohler JL; Moran BJ; Rosenthal SA; Rossi CJ; Yamada Y; Merrick G
Brachytherapy; 2011; 10(5):357-62. PubMed ID: 21497562
[TBL] [Abstract][Full Text] [Related]
2. ACR Appropriateness Criteria® definitive external beam irradiation in stage T1 and T2 prostate cancer.
Moran BJ; DeRose P; Hsu IC; Abdel-Wahab M; Arterbery VE; Ciezki JP; Frank SJ; Mohler JL; Rosenthal SA; Rossi CJ; Yamada Y; Merrick GS
Am J Clin Oncol; 2011 Dec; 34(6):636-47. PubMed ID: 22101389
[TBL] [Abstract][Full Text] [Related]
3. ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer.
Davis BJ; Taira AV; Nguyen PL; Assimos DG; D'Amico AV; Gottschalk AR; Gustafson GS; Keole SR; Liauw SL; Lloyd S; McLaughlin PW; Movsas B; Prestidge BR; Showalter TN; Vapiwala N
Brachytherapy; 2017; 16(2):266-276. PubMed ID: 27964905
[TBL] [Abstract][Full Text] [Related]
4. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland.
Merrick GS; Wallner KE; Butler WM
J Urol; 2003 May; 169(5):1643-52. PubMed ID: 12686802
[TBL] [Abstract][Full Text] [Related]
5. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1056-62. PubMed ID: 15001245
[TBL] [Abstract][Full Text] [Related]
6. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.
Taira AV; Merrick GS; Galbreath RW; Wallner KE; Butler WM
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):349-54. PubMed ID: 19467793
[TBL] [Abstract][Full Text] [Related]
7. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
[TBL] [Abstract][Full Text] [Related]
8. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
[TBL] [Abstract][Full Text] [Related]
9. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
10. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
12. American College of Radiology Appropriateness Criteria(®)--locally advanced (high-risk) prostate cancer.
Ciezki JP; Hsu IC; Abdel-Wahab M; Arterbery VE; Frank SJ; Mohler JL; Moran BJ; Rosenthal SA; Rossi CJ; Yamada Y; Merrick G;
Clin Oncol (R Coll Radiol); 2012 Feb; 24(1):43-51. PubMed ID: 21875782
[TBL] [Abstract][Full Text] [Related]
13. Controversies in prostate cancer radiotherapy: consensus development.
Lukka H; Warde P; Pickles T; Morton G; Brundage M; Souhami L;
Can J Urol; 2001 Aug; 8(4):1314-22. PubMed ID: 11564274
[TBL] [Abstract][Full Text] [Related]
14. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.
Henry AM; Al-Qaisieh B; Gould K; Bownes P; Smith J; Carey B; Bottomley D; Ash D
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):50-6. PubMed ID: 20005453
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants.
Prada PJ; Juan G; González-Suárez H; Fernández J; Jimenez I; Amón J; Cepeda M
BJU Int; 2010 Jul; 106(1):32-6. PubMed ID: 20067460
[TBL] [Abstract][Full Text] [Related]
16. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
17. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
[TBL] [Abstract][Full Text] [Related]
18. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
[TBL] [Abstract][Full Text] [Related]
19. Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone.
Ragde H; Grado GL; Nadir BS
Arch Esp Urol; 2001 Sep; 54(7):739-47. PubMed ID: 11692443
[TBL] [Abstract][Full Text] [Related]
20. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
Cookson MS; Aus G; Burnett AL; Canby-Hagino ED; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus SR; Moul JW; Tangen C; Thrasher JB; Thompson I
J Urol; 2007 Feb; 177(2):540-5. PubMed ID: 17222629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]